A CD6-targeted antibody-drug conjugate as a potential therapy for T cell–mediated disorders
Lingjun Zhang, Liping Luo, Jin Y. Chen, Rupesh Singh, William M. Baldwin, David A. Fox, Daniel J. Lindner, Daniel F. Martin, Rachel R. Caspi, Feng Lin · 2023
Read A CD6-targeted antibody-drug conjugate as a potential therapy for T cell–mediated disorders by Lingjun Zhang, Liping Luo, Jin Y. Chen, Rupesh Singh, William M. Baldwin, David A. Fox, Daniel J. Lindner, Daniel F. Martin, Rachel R. Caspi, Feng Lin (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10795824.txt.
Description
Lingjun Zhang and nine co-authors build in 2023 a targeted drug aimed only at active T cells that drive disease. T cells fuel many autoimmune ills and graft-versus-host disease. Killing all T cells would leave patients defenseless, so aim matters.
Their drug links an antibody that locks onto CD6, a T cell surface mark, to a toxin that halts cell division. Resting T cells divide little, so they shrug off the toxin. Active, fast-dividing cells take the hit. Lab tests show sharp killing of active human and mouse T cells. In mice, the drug treats two models of eye autoimmunity and one graft model, while sparing normal T cells at the same dose.
Catalog record
| CREATOR | Lingjun Zhang, Liping Luo, Jin Y. Chen, Rupesh Singh, William M. Baldwin, David A. Fox, Daniel J. Lindner, Daniel F. Martin, Rachel R. Caspi, Feng Lin |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |